stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  juno therapeutics to report second quarter  financial results on thursday august   business wire juno therapeutics to report second quarter  financial results on thursday august  july    pm eastern daylight time seattlebusiness wirejuno therapeutics inc nasdaq juno will announce financial results for the second quarter  on thursday august   after the close of usbased financial markets following the announcement juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at  pm pacific time pt   pm eastern time et analysts and investors can participate in the conference call by dialing   for domestic callers and   for international callers using the conference id  the webcast can be accessed live on the investor relations page of junos website wwwjunotherapeuticscom and will be available for replay for  days following the call about juno juno therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine juno is developing cellbased cancer immunotherapies based on chimeric antigen receptor and highaffinity t cell receptor technologies to genetically engineer t cells to recognize and kill cancer juno is developing multiple cellbased product candidates to treat a variety of bcell malignancies as well as multiple solid tumors and multiple myeloma several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date junos longterm aim is to leverage its cellbased platform to develop new product candidates that address a broader range of cancers and human diseases juno brings together innovative technologies from some of the worlds leading research institutions including the fred hutchinson cancer research center memorial sloan kettering cancer center seattle childrens research institute scri the university of california san francisco and the national cancer institute juno therapeutics has an exclusive license to the st jude children’s research hospital patented technology for cddirected product candidates that use bb which was developed by dario campana chihaya imai and st jude children’s research hospital juno’s product candidate jcar was developed in collaboration with scri and others forwardlooking statements this press release contains “forwardlooking statements” within the meaning of the private securities litigation reform act of  section a of the securities act of  and section e of the securities exchange act of  including statements regarding juno’s mission progress and business plans and the anticipated timing of the financial results release and business update forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forwardlooking statements and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of junos product development activities and clinical trials junos ability to obtain regulatory approval for and to commercialize its product candidates junos ability to establish a commerciallyviable manufacturing process and manufacturing infrastructure regulatory requirements and regulatory developments success of junos competitors with respect to competing treatments and technologies junos dependence on thirdparty collaborators and other contractors in junos research and development activities including for the conduct of clinical trials and the manufacture of junos product candidates juno’s ability to attract and retain key scientific quality controlassurance manufacturing or management personnel junos dependence on celgene for the development and commercialization outside of north america and china of juno’s cd product candidates and any other product candidates for which celgene exercises an option juno’s dependence on jw therapeutics shanghai co ltd over which juno does not exercise complete control for the development and commercialization of product candidates in china junos ability to obtain maintain or protect intellectual property rights related to its product candidates amongst others for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to junos business in general see junos quarterly report on form q filed with the securities and exchange commission on may   and juno’s other periodic reports filed with the securities and exchange commission these forwardlooking statements speak only as of the date hereof juno disclaims any obligation to update these forwardlooking statements contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom search advanced news search advanced news search log in sign up juno therapeutics’ investigational car t cell product candidate jcar shows high response rates in adults with bcell all  business wire juno therapeutics’ investigational car t cell product candidate jcar shows high response rates in adults with bcell all – durable responses and survivals observed in subset of patients who do not go to transplant – – comparable survival outcomes to transplant patients – – lower side effects in patients with minimal disease at time of car t cell infusion – june    pm eastern daylight time seattlebusiness wirejuno therapeutics inc nasdaq juno a biopharmaceutical company focused on reengaging the body’s immune system to revolutionize the treatment of cancer today announced that encouraging clinical data from jcar a chimeric antigen receptor car t cell product candidate support its strategic approach towards the commercialization of its first car t therapy updated results will be presented today in an oral presentation at the nd annual meeting of the american society for clinical oncology asco in chicago abstract  arie crown theater  pm ct “the ongoing efficacy and duration of response for a large percentage of patients specifically those who do not go on to stem cell transplant continues to be impressive” said mark j gilbert md juno’s chief medical officer “these findings provide us with further confidence about our development strategy and the ongoing phase ii rocket pivotal trial” in the phase i study presented by lead investigator jae h park md of memorial sloan kettering cancer center  adult patients with relapsed or refractory rr acute lymphoblastic leukemia all were treated with either cyclophosphamide or fludarabinecyclophosphamide followed by an infusion of jcar at the time of treatment  patients had morphologic disease burden and  patients had minimal disease burden median study followup was  months key results include complete response cr was observed in   patients with morphologic disease and in   patients with minimal disease in patients who achieved a cr and had adequate evaluation for minimal residual disease by flow cytometry or polymerase chain reaction complete molecular remission was observed in   patients with morphologic disease and in   patients with minimal disease median overall survival os for patients with minimal disease treated with jcar was not reached and that for morphologic patients treated with jcar was  months median os followup for all patients was  months durable responses and survival observed in patients who received jcar were comparable between groups that received a subsequent stem cell transplant and those that did not severe cytokine release syndrome scrs was observed in   patients and grade  or higher neurotoxicity was observed in   patients for patients with minimal disease   patients experienced scrs and   patients had grade  or higher neurotoxicity about juno’s chimeric antigen receptor car and t cell receptor tcr technologies juno’s car and tcr technologies genetically engineer t cells to recognize and kill cancer cells juno’s car t cell technology inserts a gene for a particular car into the t cell enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface juno’s tcr technology provides the t cells with a specific t cell receptor to recognize protein fragments derived from either the surface or inside the cell when either type of engineered t cell engages the target protein on the cancer cell it initiates a cellkilling response against the cancer cell jcar is an investigational product candidate and its safety and efficacy have not been established about juno juno therapeutics is building a fully integrated biopharmaceutical company focused on reengaging the body’s immune system to revolutionize the treatment of cancer founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine juno is developing cellbased cancer immunotherapies based on chimeric antigen receptor and highaffinity t cell receptor technologies to genetically engineer t cells to recognize and kill cancer juno is developing multiple cellbased product candidates to treat a variety of bcell malignancies as well as solid tumors several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date juno’s longterm aim is to leverage its cellbased platform to develop new product candidates that address a broader range of cancers and human diseases juno brings together innovative technologies from some of the world’s leading research institutions including the fred hutchinson cancer research center memorial sloan kettering cancer center seattle children’s research institute and the national cancer institute juno therapeutics has an exclusive license to the st jude children’s research hospital patented technology for cd directed product candidates that use bb which was developed by dario campana chihaya imai and st jude children’s research hospital about the celgene corporation and juno therapeutics inc collaboration celgene corporation and juno therapeutics inc are engaged in a tenyear collaboration to advance t cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on car and tcr technologies in april  celgene exercised its option under the collaboration to develop and commercialize the juno cd program outside north america and china the cd program includes investigational product candidates and their safety and efficacy have not been established forwardlooking statements this press release contains “forwardlooking statements” within the meaning of the private securities litigation reform act of  section a of the securities act of  and section e of the securities exchange act of  including statements regarding juno’s mission progress clinical benefits clinical trial results and the implications thereof planned presentations at asco clinical trial plans commercial strategy and emerging medical trends forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forwardlooking statements and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of juno’s product development activities and clinical trials juno’s ability to obtain regulatory approval for and to commercialize its product candidates juno’s ability to establish a commerciallyviable manufacturing process and manufacturing infrastructure regulatory requirements and regulatory developments success of juno’s competitors with respect to competing treatments and technologies juno’s dependence on thirdparty collaborators and other contractors in juno’s research and development activities including for the conduct of clinical trials and the manufacture of juno’s product candidates juno’s dependence on celgene for the development and commercialization outside of north america and china of juno’s cd product candidates and any other product candidates for which celgene exercises an option juno’s dependence on jw biotechnology shanghai co ltd over which juno does not exercise complete control for the development and commercialization of product candidates in china juno’s ability to obtain maintain or protect intellectual property rights related to its product candidates amongst others for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to juno’s business in general see juno’s quarterly report on form q filed with the securities and exchange commission on may   and juno’s other periodic reports filed with the securities and exchange commission these forwardlooking statements speak only as of the date hereof juno disclaims any obligation to update these forwardlooking statements contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom contacts juno therapeutics incinvestor relationsnicole keith nikkikeithjunotherapeuticscomormediachristopher williams chriswilliamsjunotherapeuticscom search advanced news search advanced news search log in sign up stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  juno therapeutics inc private company information  bloomberg july    am et biotechnology company overview of juno therapeutics inc snapshot people company overview juno therapeutics inc a biopharmaceutical company engages in developing cellbased cancer immunotherapies the company develops cellbased cancer immunotherapies based on its chimeric antigen receptor and t cell receptor technologies to genetically engineer t cells to recognize and kill cancer cells its cd product candidates include jcar that is in phase iii trials for adults with relapsed or refractory rr b cell aggressive nonhodgkin lymphoma nhl and pediatric patients with rr b cell acute lymphoblastic leukemia all jcar which is in phase iii trials to treat various b cell malignancies in patients relapsed or refractory to standard therapies and jcar that is in juno therapeutics inc a biopharmaceutical company engages in developing cellbased cancer immunotherapies the company develops cellbased cancer immunotherapies based on its chimeric antigen receptor and t cell receptor technologies to genetically engineer t cells to recognize and kill cancer cells its cd product candidates include jcar that is in phase iii trials for adults with relapsed or refractory rr b cell aggressive nonhodgkin lymphoma nhl and pediatric patients with rr b cell acute lymphoblastic leukemia all jcar which is in phase iii trials to treat various b cell malignancies in patients relapsed or refractory to standard therapies and jcar that is in phase ii trials for adult patients with rr all the company’s cd product candidate comprise jcar which is in phase i trial for pediatric and young adult patients with cdpositive rr all or rr nhl its additional product candidates include cd a cellsurface adhesion molecule to treat neuroblastoma lewis y for the treatment of lung cancer jcar which is in phase i trial for patients with refractory or recurrent pediatric neuroblastoma muc a protein for treating ovarian cancers il a cytokine to overcome the inhibitory effects ror a protein for the treatment of nonsmall cell lung triple negative breast pancreatic and prostate cancers wt an intracellular protein that is in phase iii clinical trials to treat adult myeloid leukemia and nonsmall cell lung breast pancreatic ovarian and colorectal cancers and ilra for treating glioblastoma juno therapeutics inc has collaboration agreements with celgene corporation fate therapeutics inc editas medicine inc medimmune limited and memorial sloan kettering cancer center the company was formerly known as fc therapeutics inc and changed its name to juno therapeutics inc in october  juno therapeutics inc was founded in  and is headquartered in seattle washington detailed description  westlake avenue northsuite seattle wa united statesfounded in  employees phone  wwwjunotherapeuticscom key executives for juno therapeutics inc mr hans e bishop cofounder chief executive officer president and director age  total annual compensation k mr steven d harr md chief financial officer and head of corporate development age  total annual compensation k dr hyam i levitsky md chief scientific officer and executive vice president of research age  total annual compensation k mr robert w azelby mba chief commercial officer and executive vice president age  total annual compensation k dr mark w frohlich md executive vice president of portfolio strategy age  total annual compensation k compensation as of fiscal year  juno therapeutics inc key developments juno therapeutics inc presents data from the transcend trial of jcar jun   juno therapeutics inc presented data from the transcend trial of jcar in relapsed and refractory rr aggressive b cell nonhodgkin lymphoma nhl at the  international conference on malignant lymphoma in lugano switzerland jcar is juno’s investigative chimeric antigen receptor car t cell product candidate that targets cd a protein expressed on the surface of almost all b cell malignancies and uses a defined composition of cd to cd t cells and a bb costimulatory domain which differentiates it from other current cddirected car t product candidates jcar has been granted breakthrough therapy designation by the fda for treatment of rr aggressive large b cell nhl and prime designation by the european medicines agency for treatment of rr diffuse large b cell lymphoma dlbcl a type of nhl data were presented by jeremy abramson md of massachusetts general hospital cancer center from the multicenter transcend trial abstract  a phase  study that has treated a total of  patients with rr aggressive b cell nhl including those with dlbcl or follicular lymphoma grade b as of a data cutoff date of may   transcend nhl  is a dosefinding study of jcar which is administered following fludarabinecyclophosphamide lymphodepletion patients received one of two dose levels  or  million cells they were then evaluated for pharmacokinetics disease response and safety outcomes including common car t side effects such as cytokine release syndrome crs and neurotoxicity nt notably the transcend nhl  protocol includes patients with forms of b cell nhl that would exclude them from trials of other car t product candidates including those with ecog  performance status central nervous system cns involvement of their lymphoma and those relapsed after allogeneic bone marrow transplant data for the dlbcl cohort were presented in two groups core and full the core analysis group n includes patients that represent the population that juno plans to move forward into a pivotal trial in the second half of  the core group includes patients with dlbcl de novo and transformed from follicular lymphoma that are ecog performance status  the full analysis group includes all rr patients in the dlbcl cohort n including  patients with poor performance status or niche subtypes of aggressive nhl both the core and full groups received conforming product with at least one month followup and with a data cutoff date of may   for this presentation juno therapeutics inc presents at goldman sachs th annual global healthcare conference jun  am jun   juno therapeutics inc presents at goldman sachs th annual global healthcare conference jun  am venue terranea rancho palos verdes rancho palos verdes california united states speakers hans e bishop cofounder chief executive officer president and director juno therapeutics inc updates data from the transcend trial of jcar in relapsed and refractory rr aggressive b cell nonhodgkin lymphoma jun   juno therapeutics inc announced updated data from the transcend trial of jcar in relapsed and refractory rr aggressive b cell nonhodgkin lymphoma nhl in a presentation at the  annual meeting of the american society for clinical oncology asco jcar is juno’s investigative chimeric antigen receptor car t cell product candidate that targets cd a protein expressed on the surface of almost all b cell malignancies and uses a defined composition of cd to cd t cells and a bb costimulatory domain which differentiates it from other current cddirected car t product candidates combining data across dose levels overall response rate orr is   and the complete response cr is   threemonth orr is   and cr is   of threemonth responders followed up at least six months   remain in response early data suggest a dose response relationship at three months dose level   million cells orr is   and cr is   dose level   million cells orr is   and cr is     of responding patients are alive and in follow up as of may     experienced severe crs and   experienced severe nt   did not experience any crs or nt no deaths were reported from crs or nt there was one grade  adverse event of diffuse alveolar damage which the investigator assessed as related to fludarabine cyclophosphamide and jcar treatment occurring on day  in an yearold subject who refused mechanical ventilation for progressive respiratory failure while neutropenic on growth factors and broad spectrum antibiotics and antifungals combining data across dose levels best orr is   and cr is   threemonth orr is   and cr is     experienced severe crs and   experienced severe nt   did not experience any crs or nt no deaths reported from crs or nt early data do not suggest a dose toxicity relationship at the doses tested severe crs rate is   at dose level  and   at dose level  severe nt rate is   at dose level  and   at dose level    received tocilizumab and   received dexamethasone the most frequently reported treatmentemergent adverse events were neutropenia  crs  and fatigue  similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target buyback august    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact juno therapeutics inc please visit wwwjunotherapeuticscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close juno stock price  juno therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern a breaking elon musk details tesla model  pricing range a tesla standard model  will cost  longrange model will cost   updated wall street isn’t ready for a point tumble in the dow industrials  barrons buzz robo  facebook and twitter trading on news  a wild week in washington  updated the dark side of cruises  trump to police dont be too nice  updated the highest paid athletes in the world in one chart  updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family  updated here are  coworkers you should avoid like the plague — especially in meetings to be replaced home investing quotes stocks united states juno overview compare quotes stock screener earnings calendar sectors nasdaq juno us nasdaq join td ameritrade find a broker juno therapeutics inc watchlist createjunoalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones three mustown cancer stocks for your biotechnology portfolio jun   at  pm et by michael brush juno therapeutics stock drops  after btig downgrades to sell juno therapeutics inc shares dropped  in premarket trade thursday after btig downgraded it to sell from neutral with a  price target juno shares closed at  on wednesday the company is trailing competitors like kite pharma inc and novartis ag to market and there is little demonstrative proof that juno drugs work better or have fewer lifethreatening side effects btig analyst dane leone said the companys lack of progress casts questions about its management leone said who also criticized juno chief executive hans bishop we do not think the impetus is currently in place activism but the company has built out a car t infrastructure with backing from celgene which could be valuable if managed correctly he said not all analysts agree with leones poor assessment of juno leerink analyst michael schmidt said on wednesday that we think the juno weakness on competitive fears is unwarranted and believe junos jcar product looks very competitive to both nvs and kites data when compared apples to apples more time is needed to compare the products he said with juno on track to start a pivotal study in the second half of this year after several patients in a clinical trial for junos jcar drug died last year the company later announced it would discontinue the drugs development juno and other companies are developing a similar type of cancer treatment but rivals have garnered more positive results recent clinical trial results from rival bluebird bio prompted a jp morgan analyst to christen the company the clear winner at a major cancer conference this past weekend juno shares have risen  over the last three months compared with a  rise in the sp   jun   at  am et by emma court juno therapeutics stock drops  after btig downgrades to sell juno therapeutics stock drops  after btig downgrades to sell jun   at  am et by emma court stock trading leaves congress with conflicts  big energy wants trump to slow down deregulation may   at  am et by robert schroeder juno therapeutics stock declines  after decision to not move forward with cancer drug mar   at  pm et by emma court juno therapeutics stock declines  after decision to not move forward with cancer drug mar   at  pm et by emma court juno therapeutics started at neutral with  stock price target at wedbush securities feb   at  am et by tomi kilgore juno therapeutics downgraded to market perform from outperform at raymond james dec   at  am et by tomi kilgore juno therapeutics downgraded to hold vs buy at sunttrust robinson humphrey nov   at  am et by ciara linnane dow sp  notch third straight record close nov   at  pm et by wallace witkowski juno therapeutics downgraded to market perform from outperform at fbr  co nov   at  pm et by tomi kilgore analysts say junos stock tumbles shouldnt spill over to bluebird kite pharma shares nov   at  am et by tomi kilgore update juno therapeutics plummets  in premarket trade after two patient deaths nov   at  am et by emma court juno therapeutics stock on course for biggest oneday drop since it went public in december  nov   at  am et by tomi kilgore juno therapeutics stock on track to open at record low nov   at  am et by tomi kilgore juno therapeutics stock resumes trade plunges  premarket after patient deaths prompt trial halt nov   at  am et by tomi kilgore juno therapeutics stock was down  premarket prior to trading halt nov   at  am et by tomi kilgore juno therapeutics stock halted for news to resume trade at  am et nov   at  am et by tomi kilgore juno therapeutics places leukemia trial on hold after patient death nov   at  am et by ciara linnane opinion biotech stocks have plenty of catalysts around the corner sep   at  pm et by michael brush juno’s top holder sells  million in stock douglas k bratton’s big sale drops him to the biotech’s fourthlargest holder he was an early investor jul   at  am et on barrons online peregrine pharmaceuticals faces investordriven changes the focus will be on three new directors for a fourperson board jul   at  am et on barrons online  drug stocks that can ride novartis’ coattails an fda panel approves novartis’ pioneering cancer treatment to treat leukemia more winners are possible jul   at  pm et on barrons online fda panel votes to support leukemia genetherapy treatment a group of cancer experts voted unanimously to support us regulatory approval for a firstofits kind gene therapy targeting an aggressive form of leukemia in children and young adults jul   at  pm et on the wall street journal celgene shows savvy as gilead keeps backsliding mar   at  am et on barrons seattle genetics cancerdrug trials on hold after four patient deaths dec   at  pm et on the wall street journal stocks hit fresh high nov   at  pm et on the wall street journal the problem with lilly is the problem with pharma nov   at  pm et on the wall street journal juno’s stock drops following two more deaths in cancertreatment trial nov   at  am et on the wall street journal as crude collapsed alaska capitalized on the us housing bust nov   at  am et on the wall street journal kite pharma’s lead cancer candidate shows promising results sep   at  pm et on the wall street journal two biotech ceos make m stock sales sep   at  am et on barrons novartis carts itself off sep   at  am et on barrons kite pharma’s stock upside seen slipping to  aug   at  am et on barrons stocks to watch diamondback energy imprivata american airlines juno therapeutics jul   at  am et on the wall street journal juno to resume clinical trial of anticancer treatment jul   at  pm et on the wall street journal juno shares plunge as drug trial placed on hold after patient deaths jul   at  pm et on the wall street journal where do stocks go from here look to the fed’s statements may   at  am et on the wall street journal cancer therapy may see major shift mar   at  am et on barrons juno therapeutics stock looks like a buy feb   at  am et on barrons recent news other news press releases juno therapeutics juno q earnings surprise in store although juno therapeutics juno product portfolio shows a dearth of any revenue figures the companys most advanced pipeline candidates  jcar and jcar  might drive its progress in q jul   at  pm et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha juno’s top holder sells  million in stock douglas k bratton’s big sale drops him to the biotech’s fourthlargest holder he was an early investor jul   at  am et on barrons  key things every cart investor should watch jul   at  am et on motley fool looking for value in the deal sweet spot looking for value in the deal sweet spot jul   at  am et on seeking alpha better buy celldex therapeutics inc vs juno therapeutics jul   at  am et on motley fool daily insider ratings round up  iff opk mhh merc nep daily insider ratings round up  iff opk mhh merc nep jul   at  pm et on seeking alpha  cart stocks in focus as nvs drug wins fda advisory panel vote its time to look at these  cart stocks given the interest generated by a positive fda advisory panel vote for novartis nvs experimental cart treatment jul   at  am et on zackscom betting on the cart race betting on the cart race jul   at  pm et on seeking alpha never will i ever buy preclinical biotech stocks no way jul   at  pm et on motley fool can bellicum pharmaceuticals stock bounce back jul   at  pm et on motley fool a new cancer treatment is on the way  and cancer better be scared jul   at  pm et on motley fool  drug stocks that can ride novartis’ coattails an fda panel approves novartis’ pioneering cancer treatment to treat leukemia more winners are possible jul   at  pm et on barrons how novartis fda win in cancer also could be a boon for its rivals novartis nvs grabbed a key food and drug administration approval wednesday but kite pharma kite ultimately could benefit more from regulators excitement over an emerging class of cancer drugs an analyst said thursday still shares of both drugmakers were down in afternoon trading on the stock market today novartis was down  near  as kite fell  near  rivals juno therapeutics juno and bluebird bio blue fell  jul   at  pm et on investors business daily is juno therapeutics stock still a strong buy jul   at  am et on motley fool novartis wins fda panel backing for new cart therapy treatment novartis wins fda panel backing for new cart therapy treatment jul   at  am et on seeking alpha novartis grabs key fda panel approval of experimental cancer drug a food and drug administration panel unanimously voted to recommend for approval an experimental immunooncology treatment from novartis nvs a panel attendee told investors business daily novartis drug known as ctl will go before the full fda in early october a spokesperson previously told ibd if approved it could pave the way for a similar drug from kite pharma kite dubbed ktec to grab approval as well says brad loncar jul   at  pm et on investors business daily fda panel votes to support leukemia genetherapy treatment a group of cancer experts voted unanimously to support us regulatory approval for a firstofits kind gene therapy targeting an aggressive form of leukemia in children and young adults jul   at  pm et on the wall street journal fda ad com unanimously backs novartis cart for all shares up  fda ad com unanimously backs novartis cart for all shares up  jul   at  pm et on seeking alpha novartis up  premarket as ad com review underway for cart candidate ctl novartis up  premarket as ad com review underway for cart candidate ctl jul   at  am et on seeking alpha juno therapeutics to report second quarter  financial results on thursday august  juno therapeutics to report second quarter  financial results on thursday august  jul   at  pm et on businesswire  bzx todays research reports on trending tickers diffusion pharmaceuticals inc and juno therapeutics inc todays research reports on trending tickers diffusion pharmaceuticals inc and juno therapeutics inc jul   at  am et on accesswire bcma targeted therapies  bcma targeted therapies  jul   at  pm et on pr newswire  prf tcell immunotherapy market nd edition  tcell immunotherapy market nd edition  jul   at  pm et on pr newswire  prf hans e bishop to join agilent’s board of directors hans e bishop to join agilent’s board of directors jul   at  pm et on businesswire  bzx investorsobserver releases coveredcall reports for alibaba citigroup jp morgan chase juno therapeutics inc and wells fargo  co investorsobserver releases coveredcall reports for alibaba citigroup jp morgan chase juno therapeutics inc and wells fargo  co jul   at  am et on pr newswire  prf innovative organizations choose reflektive for next generation performance management drive tripledigit yoy growth innovative organizations choose reflektive for next generation performance management drive tripledigit yoy growth jul   at  am et on pr newswire  prf todays research reports on stocks to watch juno therapeutics and ionis pharmaceuticals todays research reports on stocks to watch juno therapeutics and ionis pharmaceuticals jul   at  am et on accesswire daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics jul   at  am et on pr newswire  prf cart disease outlook  cart disease outlook  jun   at  pm et on pr newswire  prf biotech stocks showing signs of resurgence biotech stocks showing signs of resurgence jun   at  am et on pr newswire  prf todays research reports on stocks to watch juno therapeutics and antares pharma todays research reports on stocks to watch juno therapeutics and antares pharma jun   at  am et on accesswire featured company news  juno therapeutics shared updated data for transcend nhl  clinical trial at the imcl conference in switzerland featured company news  juno therapeutics shared updated data for transcend nhl  clinical trial at the imcl conference in switzerland jun   at  am et on accesswire juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma jun   at  am et on businesswire  bzx court decides it lacks jurisdiction before fda approval occurs court decides it lacks jurisdiction before fda approval occurs jun   at  am et on businesswire  bzx investors covered call reports for alcoa bluebird bio inc juno therapeutics inc tg therapeutics and xpo logistics inc include trade ideas that offer returns of  or more investors covered call reports for alcoa bluebird bio inc juno therapeutics inc tg therapeutics and xpo logistics inc include trade ideas that offer returns of  or more jun   at  am et on pr newswire  prf juno therapeutics to present at the goldman sachs th annual global healthcare conference juno therapeutics to present at the goldman sachs th annual global healthcare conference jun   at  pm et on businesswire  bzx todays research reports on stocks to watch juno therapeutics and incyte corporation todays research reports on stocks to watch juno therapeutics and incyte corporation jun   at  am et on accesswire juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma jun   at  am et on businesswire  bzx biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics may   at  am et on pr newswire  prf juno therapeutics inc juno therapeutics inc is a biopharmaceutical company which engages in the development of innovative cellular immunotherapy for the treatment of cancer it offers platforms which includes chimeric antigen receptors and tcell receptors the company was founded by hans e bishop lawrence corey richard d klausner stan riddell and robert t nelsen on august   and is headquartered in seattle wa see full profile analyst ratings sell under hold over buy number of ratings  full ratings the only bullish scenario for juno therapeutics its ceo may get fired jun   at  am et on benzingacom benzingas top upgrades downgrades for june   jun   at  am et on benzingacom vetr upgrades juno to buy amid volatile may may   at  pm et on benzingacom competitors name chg  market cap incyte corp  b repligen corp  b ziopharm oncology inc  m mirati therapeutics inc  m competitor data provided by partner content trending tickers powered by tsla  dvax  sq  ben  wy  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stock information  juno therapeutics about usmanagement teamboard of directorsnewsour sciencescientific platformcar technologytcr technologypipelinetherapeutic areasinvestor relationsstock informationnews  eventssec filingsannual reportscorporate governanceinvestor faqworking at junocurrent job openingsstock informationstock quote juno common stock pricechange volume changeintraday high week highintraday low week lowtodays opencurrencyus dollarprevious closeexchange nasdaqjul    pm etstock chartsymbol juno common stock time frame  hour  day  days  days  days  days  month  months  months  months  year  years  years  years  years  years yeartodate all data frequency every minute every  minutes every  minutes every  minutes every  minutes hourly daily weekly monthly quarterly yearly data provided by nasdaq minimum  minutes delayed view attributions and sources investor relations stock information news  events event calendar presentations sec filings annual reports  proxy statements corporate governance management team board of directors committee composition investor faq information request shareholder toolsprint pageemail pagerss feedsemail alertscontact  westlake avenue n suite  seattle wa   email inquiry juno is hiringbrowse our current job openings  juno therapeutics all rights reserved terms  conditions juno therapeutics juno q earnings surprise in store  july    zackscom join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top juno therapeutics juno q earnings surprise in store zacks equity research july   juno tsro espr zts trades from  read morehide full article juno therapeutics inc juno  free report is expected to report secondquarter  results on aug  last quarter the company delivered a negative earnings surprise of year to date juno’s shares have soared  while the industry recorded an increase of the company’s poor track record so far shows negative surprises in three of the last four quarters the average negative earnings surprise for the last four quarters is juno therapeutics inc price and eps surprisejuno therapeutics inc price and eps surprise  juno therapeutics inc quotefactors at playwith no approved products in its portfolio juno does not generate any product revenue yet thus investors’ focus will primarily be on the company’s cash burn and pipeline updatesjuno is developing cellbased cancer immunotherapies based on car and highaffinity tcr technologies this is a hot therapeutic area with huge commercial potential presently the company’s most advanced pipeline candidates include jcar and jcar which use car tcell technology to target cdjcar is in a phase i study for nonhodgkin lymphoma nhl and in a phase iii study in pediatric and young adults with acute lymphoblastic leukemia rr all a pivotal trial for jcar in rr dlbcl diffuse large bcell lymphoma is expected to start in  the company plans to bring jcar to the market for nhl as early as  and for multiple indications by the end of encouraging data from an earlystage study evalauting jcar in patients with chronic lymphocytic leukemia cll who failed treatment with ibrutinib was presented in dec  insights from studies of jcar are being applied to the development of jcar for the treatment of bcell malignancieshowever the company faced a major setback last year related to the development of its lead pipeline candidate jcar in nov  juno announced that it is discontinuing the development of jcar for rr all due to the toxicity witnessed in a phase ii rocket studywe note that at the time of releasing the firstquarter results juno has maintained its expectations of cash burn of – million for earnings whispersour proven model does not conclusively show that juno is likely to beat estimates this quarter this is because a stock needs to have both a positive earnings esp and a zacks rank  strong buy  buy or  hold for this to happen this is not the case here as you will see belowzacks esp the earnings esp which represents the difference between the most accurate estimate and the zacks consensus estimate is  this is because both the most accurate estimate and the zacks consensus estimate are pegged at a loss of  centsyou can uncover the best stocks to buy or sell before they’re reported with our earnings esp filterzacks rank although juno’s zacks rank  buy increases the predictive power of esp its  earnings esp makes surprise prediction difficultwe caution against all sellrated stocks  or  going into the earnings announcement especially when the company is seeing negative estimate revisionsstocks that warrant a lookhere are some other worthconsidering health care stocks which have the right combination of elements per our model to post an earnings beat this quarterzoetis inc zts  free report is scheduled to release results on aug  with an earnings esp of  and a zacks rank  you can see the complete list of today’s zacks  rank stocks heretesaro inc tsro  free report is scheduled to release results on aug  the company has an earnings esp of  and a zacks rank esperion therapeutics inc espr  free report is expected to release results on aug  the company has an earnings esp of  and a zacks rank more stock news tech opportunity worth  billion in                  from driverless cars to artificial intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the futurezacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential see these stocks now indepth zacks research for the tickers above normally  each  click below to receive one report free juno therapeutics inc juno  free report tesaro inc tsro  free report esperion therapeutics inc espr  free report zoetis inc zts  free report  more from zacks analyst blog insperity nsp q earnings whats in the cards glu mobile gluu q earnings whats in the cards dow  stock roundup caterpillar dupont mcd pg beat can royal caribbean rcl pull off a surprise in q earnings › ‹ you may like q earnings season past the halfway mark us telecom price competition to intensify top research reports for facebook cocacola  verizon new technologies give us telecom more reasons to grow › ‹ zacks  breakout stocksfor july  free report for zackscom visitors only our experts cut down  zacks rank  strong buys to the  that are most likely to jump in price immediately for  years the full strong buy list has averaged a stellar  per year see its  best stocks now close this panel x up next can exco resources xco q earnings surprise most read  years of investing wisdom in  minutes q earnings season past the halfway mark top research reports for facebook cocacola  verizon friday finish line jimmy choo sale q earnings roundup  more buy the amazon dip with etfs › ‹ juno therapeutics juno q earnings surprise in store  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search juno therapeutics juno q earnings surprise in store july    pm edt by zacks equity research zackscom shutterstock photo juno therapeutics inc juno is expected to report secondquarter  results on aug  last quarter the company delivered a negative earnings surprise of  year to date junos shares have soared  while the industry recorded an increase of  the companys poor track record so far shows negative surprises in three of the last four quarters the average negative earnings surprise for the last four quarters is  juno therapeutics inc price and eps surprise juno therapeutics inc price and eps surprise  juno therapeutics inc quote factors at play with no approved products in its portfolio juno does not generate any product revenue yet thus investors focus will primarily be on the companys cash burn and pipeline updates juno is developing cellbased cancer immunotherapies based on car and highaffinity tcr technologies this is a hot therapeutic area with huge commercial potential presently the companys most advanced pipeline candidates include jcar and jcar which use car tcell technology to target cd jcar is in a phase i study for nonhodgkin lymphoma nhl and in a phase iii study in pediatric and young adults with acute lymphoblastic leukemia rr all a pivotal trial for jcar in rr dlbcl diffuse large bcell lymphoma is expected to start in  the company plans to bring jcar to the market for nhl as early as  and for multiple indications by the end of  encouraging data from an earlystage study evalauting jcar in patients with chronic lymphocytic leukemia cll who failed treatment with ibrutinib was presented in dec  insights from studies of jcar are being applied to the development of jcar for the treatment of bcell malignancies however the company faced a major setback last year related to the development of its lead pipeline candidate jcar in nov  juno announced that it is discontinuing the development of jcar for rr all due to the toxicity witnessed in a phase ii rocket study we note that at the time of releasing the firstquarter results juno has maintained its expectations of cash burn of  million for  earnings whispers our proven model does not conclusively show that juno is likely to beat estimates this quarter this is because a stock needs to have both a positive earnings esp  and a zacks rank  strong buy  buy or  hold for this to happen this is not the case here as you will see below zacks esp  the earnings esp which represents the difference between the most accurate estimate and the zacks consensus estimate is  this is because both the most accurate estimate and the zacks consensus estimate are pegged at a loss of  centsyou can uncover the best stocks to buy or sell before theyre reported with our earnings esp filter  zacks rank although junos zacks rank  buy increases the predictive power of esp its  earnings esp makes surprise prediction difficult we caution against all sellrated stocks  or  going into the earnings announcement especially when the company is seeing negative estimate revisions stocks that warrant a look here are some other worthconsidering health care stocks which have the right combination of elements per our model to post an earnings beat this quarter zoetis inc zts is scheduled to release results on aug  with an earnings esp of  and a zacks rank  you can see  the complete list of todays zacks  rank stocks here  tesaro inc tsro is scheduled to release results on aug  the company has an earnings esp of  and a zacks rank  esperion therapeutics inc espr is expected to release results on aug  the company has an earnings esp of  and a zacks rank  more stock news tech opportunity worth  billion in                  from driverless cars to artificial intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the future zacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential see these stocks now want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report juno therapeutics inc juno free stock analysis report tesaro inc tsro free stock analysis report esperion therapeutics inc espr free stock analysis report zoetis inc zts free stock analysis report to read this article on zackscom click here zacks investment research the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of nasdaq inc this article appears in investing  business  earnings  stocks referenced symbols juno  tsro  espr  zts more from zackscom subscribe  cart stocks in focus as nvs drug wins fda advisory panel vote pricing competition remain headwinds for pharma in  why is kite pharma kite stock up close to  this year related earnings articles subscribe  key predictions for apples q earnings report   pm q earnings season past the halfway mark   pm insperity nsp q earnings whats in the cards   pm contributorzackscom equity research follow on most popular highest rated mitel to acquire shoretel  quick facts sientra completes acquisition of miramar labs® seagate technology plc q profit rises  ledgerx gets us approval for derivatives on digital currencies us fines frontier american and delta for violating consumer shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the mitel to acquire shoretel  quick facts miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated research brokers before you trade compare online brokers want to trade fx visit our forex broker center  find a credit card select a credit card product by  card type  credit score  card issuer select an offer  apr credit cardsairline credit cardsbalance transfer credit cardsbusiness credit cardscash back credit cardscharge cardscharge cards for businessemv smart chipsgas cards  auto rewardshome improvement rewards credit cardsinstant approval credit cardslow interest credit cardsno annual fee credit cardsno foreign transaction fee credit cardspoints rewards credit cardsprepaid  debit cardsreward credit cardsstudent credit cardstop  best credit card deals and offers bad creditcredit quality averagecredit quality excellentcredit quality faircredit quality goodlimited or no credit historypersonal loans american expressamerican express airline cardsamerican express business cardsamerican express cash back credit cardsamerican express charge cardsbarclaycardcapital onecapital one cash backcapital one fair creditcapital one milescapital one pointscapital one prepaid credit cardschaseciti credit cardsdiscoverdiscover cashbackdiscover milesdiscover student credit cardsmastercard credit cardsus bankusaausaa savingsvisa credit cards search data provided by bankratecom stocks referenced juno  rate it tsro  rate it espr  rate it zts  rate it closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex juno stock price  juno therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern a breaking elon musk details tesla model  pricing range a tesla standard model  will cost  longrange model will cost   updated wall street isn’t ready for a point tumble in the dow industrials  barrons buzz robo  facebook and twitter trading on news  a wild week in washington  updated the dark side of cruises  trump to police dont be too nice  updated the highest paid athletes in the world in one chart  updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family  updated here are  coworkers you should avoid like the plague — especially in meetings to be replaced home investing quotes stocks united states juno overview compare quotes stock screener earnings calendar sectors nasdaq juno us nasdaq join td ameritrade find a broker juno therapeutics inc watchlist createjunoalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones three mustown cancer stocks for your biotechnology portfolio jun   at  pm et by michael brush juno therapeutics stock drops  after btig downgrades to sell juno therapeutics inc shares dropped  in premarket trade thursday after btig downgraded it to sell from neutral with a  price target juno shares closed at  on wednesday the company is trailing competitors like kite pharma inc and novartis ag to market and there is little demonstrative proof that juno drugs work better or have fewer lifethreatening side effects btig analyst dane leone said the companys lack of progress casts questions about its management leone said who also criticized juno chief executive hans bishop we do not think the impetus is currently in place activism but the company has built out a car t infrastructure with backing from celgene which could be valuable if managed correctly he said not all analysts agree with leones poor assessment of juno leerink analyst michael schmidt said on wednesday that we think the juno weakness on competitive fears is unwarranted and believe junos jcar product looks very competitive to both nvs and kites data when compared apples to apples more time is needed to compare the products he said with juno on track to start a pivotal study in the second half of this year after several patients in a clinical trial for junos jcar drug died last year the company later announced it would discontinue the drugs development juno and other companies are developing a similar type of cancer treatment but rivals have garnered more positive results recent clinical trial results from rival bluebird bio prompted a jp morgan analyst to christen the company the clear winner at a major cancer conference this past weekend juno shares have risen  over the last three months compared with a  rise in the sp   jun   at  am et by emma court juno therapeutics stock drops  after btig downgrades to sell juno therapeutics stock drops  after btig downgrades to sell jun   at  am et by emma court stock trading leaves congress with conflicts  big energy wants trump to slow down deregulation may   at  am et by robert schroeder juno therapeutics stock declines  after decision to not move forward with cancer drug mar   at  pm et by emma court juno therapeutics stock declines  after decision to not move forward with cancer drug mar   at  pm et by emma court juno therapeutics started at neutral with  stock price target at wedbush securities feb   at  am et by tomi kilgore juno therapeutics downgraded to market perform from outperform at raymond james dec   at  am et by tomi kilgore juno therapeutics downgraded to hold vs buy at sunttrust robinson humphrey nov   at  am et by ciara linnane dow sp  notch third straight record close nov   at  pm et by wallace witkowski juno therapeutics downgraded to market perform from outperform at fbr  co nov   at  pm et by tomi kilgore analysts say junos stock tumbles shouldnt spill over to bluebird kite pharma shares nov   at  am et by tomi kilgore update juno therapeutics plummets  in premarket trade after two patient deaths nov   at  am et by emma court juno therapeutics stock on course for biggest oneday drop since it went public in december  nov   at  am et by tomi kilgore juno therapeutics stock on track to open at record low nov   at  am et by tomi kilgore juno therapeutics stock resumes trade plunges  premarket after patient deaths prompt trial halt nov   at  am et by tomi kilgore juno therapeutics stock was down  premarket prior to trading halt nov   at  am et by tomi kilgore juno therapeutics stock halted for news to resume trade at  am et nov   at  am et by tomi kilgore juno therapeutics places leukemia trial on hold after patient death nov   at  am et by ciara linnane opinion biotech stocks have plenty of catalysts around the corner sep   at  pm et by michael brush juno’s top holder sells  million in stock douglas k bratton’s big sale drops him to the biotech’s fourthlargest holder he was an early investor jul   at  am et on barrons online peregrine pharmaceuticals faces investordriven changes the focus will be on three new directors for a fourperson board jul   at  am et on barrons online  drug stocks that can ride novartis’ coattails an fda panel approves novartis’ pioneering cancer treatment to treat leukemia more winners are possible jul   at  pm et on barrons online fda panel votes to support leukemia genetherapy treatment a group of cancer experts voted unanimously to support us regulatory approval for a firstofits kind gene therapy targeting an aggressive form of leukemia in children and young adults jul   at  pm et on the wall street journal celgene shows savvy as gilead keeps backsliding mar   at  am et on barrons seattle genetics cancerdrug trials on hold after four patient deaths dec   at  pm et on the wall street journal stocks hit fresh high nov   at  pm et on the wall street journal the problem with lilly is the problem with pharma nov   at  pm et on the wall street journal juno’s stock drops following two more deaths in cancertreatment trial nov   at  am et on the wall street journal as crude collapsed alaska capitalized on the us housing bust nov   at  am et on the wall street journal kite pharma’s lead cancer candidate shows promising results sep   at  pm et on the wall street journal two biotech ceos make m stock sales sep   at  am et on barrons novartis carts itself off sep   at  am et on barrons kite pharma’s stock upside seen slipping to  aug   at  am et on barrons stocks to watch diamondback energy imprivata american airlines juno therapeutics jul   at  am et on the wall street journal juno to resume clinical trial of anticancer treatment jul   at  pm et on the wall street journal juno shares plunge as drug trial placed on hold after patient deaths jul   at  pm et on the wall street journal where do stocks go from here look to the fed’s statements may   at  am et on the wall street journal cancer therapy may see major shift mar   at  am et on barrons juno therapeutics stock looks like a buy feb   at  am et on barrons recent news other news press releases juno therapeutics juno q earnings surprise in store although juno therapeutics juno product portfolio shows a dearth of any revenue figures the companys most advanced pipeline candidates  jcar and jcar  might drive its progress in q jul   at  pm et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha juno’s top holder sells  million in stock douglas k bratton’s big sale drops him to the biotech’s fourthlargest holder he was an early investor jul   at  am et on barrons  key things every cart investor should watch jul   at  am et on motley fool looking for value in the deal sweet spot looking for value in the deal sweet spot jul   at  am et on seeking alpha better buy celldex therapeutics inc vs juno therapeutics jul   at  am et on motley fool daily insider ratings round up  iff opk mhh merc nep daily insider ratings round up  iff opk mhh merc nep jul   at  pm et on seeking alpha  cart stocks in focus as nvs drug wins fda advisory panel vote its time to look at these  cart stocks given the interest generated by a positive fda advisory panel vote for novartis nvs experimental cart treatment jul   at  am et on zackscom betting on the cart race betting on the cart race jul   at  pm et on seeking alpha never will i ever buy preclinical biotech stocks no way jul   at  pm et on motley fool can bellicum pharmaceuticals stock bounce back jul   at  pm et on motley fool a new cancer treatment is on the way  and cancer better be scared jul   at  pm et on motley fool  drug stocks that can ride novartis’ coattails an fda panel approves novartis’ pioneering cancer treatment to treat leukemia more winners are possible jul   at  pm et on barrons how novartis fda win in cancer also could be a boon for its rivals novartis nvs grabbed a key food and drug administration approval wednesday but kite pharma kite ultimately could benefit more from regulators excitement over an emerging class of cancer drugs an analyst said thursday still shares of both drugmakers were down in afternoon trading on the stock market today novartis was down  near  as kite fell  near  rivals juno therapeutics juno and bluebird bio blue fell  jul   at  pm et on investors business daily is juno therapeutics stock still a strong buy jul   at  am et on motley fool novartis wins fda panel backing for new cart therapy treatment novartis wins fda panel backing for new cart therapy treatment jul   at  am et on seeking alpha novartis grabs key fda panel approval of experimental cancer drug a food and drug administration panel unanimously voted to recommend for approval an experimental immunooncology treatment from novartis nvs a panel attendee told investors business daily novartis drug known as ctl will go before the full fda in early october a spokesperson previously told ibd if approved it could pave the way for a similar drug from kite pharma kite dubbed ktec to grab approval as well says brad loncar jul   at  pm et on investors business daily fda panel votes to support leukemia genetherapy treatment a group of cancer experts voted unanimously to support us regulatory approval for a firstofits kind gene therapy targeting an aggressive form of leukemia in children and young adults jul   at  pm et on the wall street journal fda ad com unanimously backs novartis cart for all shares up  fda ad com unanimously backs novartis cart for all shares up  jul   at  pm et on seeking alpha novartis up  premarket as ad com review underway for cart candidate ctl novartis up  premarket as ad com review underway for cart candidate ctl jul   at  am et on seeking alpha juno therapeutics to report second quarter  financial results on thursday august  juno therapeutics to report second quarter  financial results on thursday august  jul   at  pm et on businesswire  bzx todays research reports on trending tickers diffusion pharmaceuticals inc and juno therapeutics inc todays research reports on trending tickers diffusion pharmaceuticals inc and juno therapeutics inc jul   at  am et on accesswire bcma targeted therapies  bcma targeted therapies  jul   at  pm et on pr newswire  prf tcell immunotherapy market nd edition  tcell immunotherapy market nd edition  jul   at  pm et on pr newswire  prf hans e bishop to join agilent’s board of directors hans e bishop to join agilent’s board of directors jul   at  pm et on businesswire  bzx investorsobserver releases coveredcall reports for alibaba citigroup jp morgan chase juno therapeutics inc and wells fargo  co investorsobserver releases coveredcall reports for alibaba citigroup jp morgan chase juno therapeutics inc and wells fargo  co jul   at  am et on pr newswire  prf innovative organizations choose reflektive for next generation performance management drive tripledigit yoy growth innovative organizations choose reflektive for next generation performance management drive tripledigit yoy growth jul   at  am et on pr newswire  prf todays research reports on stocks to watch juno therapeutics and ionis pharmaceuticals todays research reports on stocks to watch juno therapeutics and ionis pharmaceuticals jul   at  am et on accesswire daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics jul   at  am et on pr newswire  prf cart disease outlook  cart disease outlook  jun   at  pm et on pr newswire  prf biotech stocks showing signs of resurgence biotech stocks showing signs of resurgence jun   at  am et on pr newswire  prf todays research reports on stocks to watch juno therapeutics and antares pharma todays research reports on stocks to watch juno therapeutics and antares pharma jun   at  am et on accesswire featured company news  juno therapeutics shared updated data for transcend nhl  clinical trial at the imcl conference in switzerland featured company news  juno therapeutics shared updated data for transcend nhl  clinical trial at the imcl conference in switzerland jun   at  am et on accesswire juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma jun   at  am et on businesswire  bzx court decides it lacks jurisdiction before fda approval occurs court decides it lacks jurisdiction before fda approval occurs jun   at  am et on businesswire  bzx investors covered call reports for alcoa bluebird bio inc juno therapeutics inc tg therapeutics and xpo logistics inc include trade ideas that offer returns of  or more investors covered call reports for alcoa bluebird bio inc juno therapeutics inc tg therapeutics and xpo logistics inc include trade ideas that offer returns of  or more jun   at  am et on pr newswire  prf juno therapeutics to present at the goldman sachs th annual global healthcare conference juno therapeutics to present at the goldman sachs th annual global healthcare conference jun   at  pm et on businesswire  bzx todays research reports on stocks to watch juno therapeutics and incyte corporation todays research reports on stocks to watch juno therapeutics and incyte corporation jun   at  am et on accesswire juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma jun   at  am et on businesswire  bzx biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics may   at  am et on pr newswire  prf juno therapeutics inc juno therapeutics inc is a biopharmaceutical company which engages in the development of innovative cellular immunotherapy for the treatment of cancer it offers platforms which includes chimeric antigen receptors and tcell receptors the company was founded by hans e bishop lawrence corey richard d klausner stan riddell and robert t nelsen on august   and is headquartered in seattle wa see full profile analyst ratings sell under hold over buy number of ratings  full ratings the only bullish scenario for juno therapeutics its ceo may get fired jun   at  am et on benzingacom benzingas top upgrades downgrades for june   jun   at  am et on benzingacom vetr upgrades juno to buy amid volatile may may   at  pm et on benzingacom competitors name chg  market cap incyte corp  b repligen corp  b ziopharm oncology inc  m mirati therapeutics inc  m competitor data provided by partner content trending tickers powered by tsla  dvax  sq  ben  wy  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft contact us  juno therapeutics about us our people our values our story the science our platform car technology tcr technology our pipeline patients work at juno work life juno attributes seattle life open positions search investors press contact us contact us contact us name email inquiry general information business development media investor relations patients medicalhealthcare provider employment verification medical information how can we help submit juno therapeutics inc headquarters  dexter avenue north suite  seattle wa  call  juno therapeutics inc manufacturing plant – bothell washington  th place se bothell wa  waltham office  winter st waltham ma  juno therapeutics gmbh – gottingen germany rudolfwissellstraße   göttingen germany juno therapeutics gmbh – munich germany grillparzerstr   munich germany juno car t cell therapies are investigational and not fda approved × you are now leaving juno therapeutics continue cancel continue  or  cancel junos dedicated team  juno therapeutics about us our people our values our story the science our platform car technology tcr technology our pipeline patients work at juno work life juno attributes seattle life open positions search investors press contact us a commitment to excellence we have a dedicated team of people across our organization from our scientific founders to our most recent hires who are driven to make an impact and transform lives through the work they do management team board of directors hans bishop president  ceo steve harr md cfo  head of corporate development sunil agarwal md president of research and development hyam levitsky md evp chief scientific officer bob azelby evp chief commercial officer barney cassidy jd general counsel  secretary mark gilbert md svp chief medical officer corsee sanders phd evp  head of development operations elizabeth smith svp regulatory and quality assurance andy walker phd svp manufacturing lothar germeroth phd svp managing director robin andrulevich svp people hal barron director hans bishop president  ceo thomas daniel director anthony evnin director jay flatley director richard klausner director  cofounder robert nelsen director  cofounder howard pien chairman  director mary agnes maggie wilderotter director rupert vessey ma bm bch frcp dphil director our founding partners critical to our futurejuno has partnered with leading medical and research organizations to advance a broad pipeline of novel investigational immunotherapies including fred hutchinson cancer research center memorial sloan kettering cancer center and seattle children’s research institute fred hutchinson cancer research center seattle wa memorial sloan kettering cancer center new york ny seattle children’s research institute seattle wa juno car t cell therapies are investigational and not fda approved × you are now leaving juno therapeutics continue cancel continue  or  cancel junos cancer therapy research pipeline  juno therapeutics about us our people our values our story the science our platform car technology tcr technology our pipeline patients work at juno work life juno attributes seattle life open positions search investors press contact us developing bestinclass therapies juno’s pipeline of investigational car t cell product candidates applies our car and tcr technologies against a variety of cancer targets therapeutic area view all all acute lymphoblastic leukemia acute myeloid leukemia lung cancer mesothelioma multiple myeloma neuroblastoma nonhodgkin lymphoma nonsmall cell lung cancer ovarian cancer triplenegative breast cancer nhlcd  jcar phase  nhl nonhodgkin lymphoma target cd is a protein expressed on the surface of almost all bcell leukemias and lymphomas trial number trial description trial number nct trial description study evaluating the safety and pharmacokinetics of jcar in bcell nonhodgkin lymphoma nhllearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations birmingham al university of alabamabirmingham duarte ca city of hope chicago il northwestern university contact leo i gordon md  boston ma massachusetts general hospital contact jeremy abramson md  boston ma beth israel deaconess medical center omaha ne university of nebraska medical center contact susan blumel rn  new york ny memorial sloan kettering cancer center contact lia palomba md  houston tx md anderson cancer center contact michael wang md  seattle wa fred hutchinson cancer research center contact kieuthu bui rn  about nonhodgkin lymphoma nonhodgkin lymphoma nhl is not a single disease but rather a group of several closely related cancers with different patterns of treatment over  cases of nhl are diagnosed in the us each year nhl is typically divided into aggressive fastgrowing and indolent slowgrowing subtypes juno is planning to evaluate multiple product candidates in phase  trials for common types of relapsed or refractory rr b cell nhl of both aggressive and indolent subtypes adapted from american cancer society cancer a – z nhlcd  jcar combinations phase  nhl nonhodgkin lymphoma target cd is a protein expressed on the surface of almost all bcell leukemias and lymphomas trial number trial description trial number nct trial description jcar and durvalumab in treating patients with relapsed or refractory bcell nonhodgkin lymphomalearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations seattle wa fred hutchuniversity of washington cancer consortium contact immunotherapy trials intake scca  about nonhodgkin lymphoma nonhodgkin lymphoma nhl is not a single disease but rather a group of several closely related cancers with different patterns of treatment over  cases of nhl are diagnosed in the us each year nhl is typically divided into aggressive fastgrowing and indolent slowgrowing subtypes juno is planning to evaluate multiple product candidates in phase  trials for common types of relapsed or refractory rr b cell nhl of both aggressive and indolent subtypes adapted from american cancer society cancer a – z pediatric allcd  jcar phase  pediatric all acute lymphoblastic leukemia target cd is a protein expressed by most bcell malignancies including acute lymphoblastic leukemia nonhodgkin lymphoma and chronic lymphocytic leukemia trial number trial description trial number nct trial description anticd chimeric receptor t cells in pediatric and young adults with recurrent or refractory cdexpressing b cell malignancieslearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations bethesda md national institutes of health clinical center  rockville pike contact for more information at the nih clinical center contact national cancer institute referral office  about acute lymphoblastic leukemia acute lymphoblastic leukemia all is an uncontrolled proliferation of lymphoblasts which are immature white blood cells the lymphoblasts which are produced in the bone marrow cause damage and death by inhibiting the production of normal cells approximately  patients are diagnosed with all in the united states each year and although just over half of the new diagnoses are in adult patients the vast majority of the approximately  deaths per year occur in adults there are two main types of all b cell all and t cell all approximately  of cases of all are b cell all which we aim to address with our cd product candidates adapted from american cancer society cancer a – z nhlcd  jcar phase  nhl nonhodgkin lymphoma target cd is a protein expressed by most bcell malignancies including acute lymphoblastic leukemia nonhodgkin lymphoma and chronic lymphocytic leukemia trial number trial description trial number nct trial description anticd chimeric receptor t cells in pediatric and young adults with recurrent or refractory cdexpressing b cell malignancieslearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations bethesda md national institutes of health clinical center  rockville pike contact for more information at the nih clinical center contact national cancer institute referral office  about nonhodgkin lymphoma nonhodgkin lymphoma nhl is not a single disease but rather a group of several closely related cancers with different patterns of treatment over  cases of nhl are diagnosed in the us each year nhl is typically divided into aggressive fastgrowing and indolent slowgrowing subtypes juno is planning to evaluate multiple product candidates in phase  trials for common types of relapsed or refractory rr b cell nhl of both aggressive and indolent subtypes adapted from american cancer society cancer a – z multiple myelomabcma phase  multiple myeloma target bcell maturation antigen bcma is expressed on all plasma cells including cancerous plasma cells in multiple myeloma trial number trial description trial number nct trial description bcma targeted car t cells for the treatment of multiple myelomalearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations new york ny memorial sloan kettering cancer center contact sham mailankody md  about multiple myeloma multiple myeloma is a form of blood cancer that occurs when white blood cells known as plasma cells which are typically found in the bone marrow grow out of control and develop into tumors approximately  new cases of multiple myeloma will be diagnosed this year in the us there are few known risk factors for developing this disease and it may not cause signs or symptoms that would lead to a diagnosis until it has advanced to the kidneys and other organs adapted from american cancer society cancer a – z amlwt  jtcr phase phase  aml acute myeloid leukemia target wt is an intracellular protein that is overexpressed in a number of cancers including acute myeloid leukemia and nonsmall cell lung breast pancreatic ovarian and colorectal cancers trial number trial description trial number nct trial description laboratorytreated t cells in treating patients with highrisk relapsed acute myeloid leukemia myelodysplastic syndrome or chronic myelogenous leukemia previously treated with donor stem cell transplantlearn more at clinicaltrialsgov ›enrollment status suspended locations seattle wa fred hutchuniversity of washington cancer consortium about acute myeloid leukemia every year about  people are diagnosed with aml in the united states with the incidence increasing in the advanced age group aml is often incurable with standard systemic therapy despite the many advances in the field of hematopoietic cell transplant hct relapse after transplantation continues to be a major problem particularly in patients entering hct with high riskpoor prognosis diseases adapted from american cancer society cancer a – z nsclc mesotheliomawt  jtcr phase phase  nsclc mesothelioma nonsmall cell lung cancer mesothelioma target wt is an intracellular protein that is overexpressed in a number of cancers including acute myeloid leukemia and nonsmall cell lung breast pancreatic ovarian and colorectal cancers trial number trial description trial number nct trial description genetically modified t cells in treating patients with stage iiiiv nonsmall cell lung cancer or mesotheliomalearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations seattle wa fred hutchuniversity of washington cancer consortium contact sylvia m lee  about nonsmall cell lung cancer nonsmall cell lung cancer nsclc is the most common type of lung cancer accounting for up to  of all lung cancer diagnoses in the us within nsclc there are many subtypes of the disease depending on the different types of lung cells immunotherapy for nsclc is a newer type of treatment that boosts a person’s immune system to help fight their cancer adapted from american cancer society cancer a – z about mesothelioma mesothelioma is a rare and aggressive type of cancer that grows in the lining of the lungs or abdomen or in the lining around the heart cavity it most typically is found in the lungs the most common risk factor for mesothelioma is exposure to asbestos often the disease is not diagnosed until it has advanced and affected many organs at this time there is no cure for mesothelioma adapted from american cancer society cancer a – z pediatric neuroblastomalcam  jcar phase  pediatric neuroblastoma target lcam also known as cd is a cellsurface adhesion molecule that is overexpressed in neuroblastoma and there is increasing evidence of aberrant expression in a variety of solid organ tumors including glioblastoma lung pancreatic and ovarian cancers trial number trial description trial number nct trial description engineered neuroblastoma cellular immunotherapy encitlearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations seattle wa seattle childrens hospital contact julie park  about neuroblastoma neuroblastoma is a type of cancer that starts in the early nerve cells known as neuroblasts of infants and young children under the age of  it accounts for approximately  percent of all cancers in children with about  new cases in the us each year in infants it is the most common solid cancer adapted from american cancer society cancer a – z ovarianmuc  jcar phase  ovarian ovarian cancer target muc is a protein overexpressed in the majority of ovarian cancers blood levels of ca a protein from the cleavage of muc can be correlated with ovarian cancer progression trial number trial description trial number nct trial description cyclophosphamide followed by intravenous and intraperitoneal infusion of autologous t cells genetically engineered to secrete il and to target the mucecto antigen in patients with recurrent mucecto solid tumorslearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations new york ny memorial sloan kettering cancer center contact roisin ocearbhaill md  about ovarian cancer ovarian cancer mainly affects women over the age of  with more than  diagnoses in the us this year while all women are at risk of developing ovarian cancer those with the brca gene mutation are at increased risk for developing this type of cancer treatment depends on the type of cancer and the stage of the disease adapted from american cancer society cancer a – z nsclc breastror  jcar phase  nsclc breast nonsmall cell lung cancer triplenegative breast cancer target ror is a protein overexpressed on a wide variety of cancers including a subset of nonsmall cell lung cancer triplenegative breast cancer pancreatic cancer and prostate cancer it is highly expressed on b cell chronic lymphocytic leukemia and mantle cell lymphoma trial number trial description trial number nct trial description genetically modified tcell therapy in treating patients with advanced ror malignancieslearn more at clinicaltrialsgov ›enrollment status recruitingplease contact the trial center for more information on eligibility locations seattle wa fred hutchuniversity of washington cancer consortium about nonsmall cell lung cancer nonsmall cell lung cancer nsclc is the most common type of lung cancer accounting for up to  of all lung cancer diagnoses in the us within nsclc there are many subtypes of the disease depending on the different types of lung cells immunotherapy for nsclc is a newer type of treatment that boosts a person’s immune system to help fight their cancer adapted from american cancer society cancer a – z about triplenegative breast cancer breast cancer is the second most common cancer in american women with more than  new cases diagnosed this year in triplenegative breast cancer the breast cancer cells test negative for the hormones estrogen er and progesterone pr and the protein her her as a result this type of cancer does not respond to hormonal therapy or therapies that target her approximately  of breast cancers fall into this category and are more common in young women and those who are africanamerican or hispaniclatina adapted from american cancer society cancer a – z lung cancerley phase  lung cancer target the lewis y ley blood group antigen is highly expressed in a number of solid tumors including lung colorectal gastric breast and ovarian cancers trial number trial description about lung cancer lung cancer is the second most common cancer in men and women after skin cancer and is typically diagnosed at an advanced stage most lung cancer diagnoses are related to smoking or exposure to environmental factors but some occur in people with no known risk factors recommended treatments vary depending on the type of lung cancer and the stage of the disease adapted from american cancer society cancer a – z to learn more about juno’s expanded access policy please visit our guidelines learn moreexplore car t science more indepth learn about our therapeutic areas and explore additional resources at the links below hcps visit cartcellsciencecom view our patients page juno car t cell therapies are investigational and not fda approved × you are now leaving juno therapeutics continue cancel continue  or  cancel open positions  juno therapeutics about us our people our values our story the science our platform car technology tcr technology our pipeline patients work at juno work life juno attributes seattle life open positions search investors press contact us current job openings we are continually bringing innovative minds to juno—fearless people who can imagine the possibilities and deliver with a sense of urgency having trouble submitting your resume to junoplease email jobsjunotherapeuticscom and tell us what’s the problem juno car t cell therapies are investigational and not fda approved × you are now leaving juno therapeutics continue cancel continue  or  cancel home about us our people our values our story the science our platform car technology tcr technology our pipeline patients work at juno work life juno attributes seattle life open positions search investors press contact us changing medicine for good it’s an audacious mission—a quest to radically change the course of medicine we’re aligning our investments in scientific research manufacturing and most of all people to change the way cancer and other serious diseases are treated learn more advanced immunotherapies for cancer patients our investigational technology programs t cells to recognize and attack cancer cells it’s a revolutionary approach for the treatment of cancer and other serious diseases learn about car and tcr technologies in the pipeline we have multiple product candidates in development for a variety of cancers including nonhodgkin lymphoma nhl acute lymphoblastic leukemia all and chronic lymphocytic leukemia cll see an indepth view of our current pipeline work at juno if you’re interested in a career that pushes the bounds of what is possible and work that has the potential to revolutionize medicine then we would like to hear from you view open positions and learn about life at juno patients come firstif you are interested in learning more about car t cell therapy and the potential treatment process we break down the process for you and direct you to resources provided by the leading blood cancer advocacy organizations visit our patients page recent news jul  juno therapeutics to report second quarter  financial results on thursday august  jun  juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma view all news and events juno on twitter everything juno therapeuticsjunothera juno’s sunil agarwal writes for forbes car t therapy is here to stay httpstcosjmdostgna impt info httpstcomdduthgou jul  reply retweet favorite follow us on twitter investorsjuno therapeutics inc nasdaq juno is a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer visit our ir site pressread the latest announcements about our progress and our people and request juno media assets visit our press room juno car t cell therapies are investigational and not fda approved × you are now leaving juno therapeutics continue cancel continue  or  cancel juno therapeutics juno q earnings surprise in store  mrtopstepcom skip to content want to advertise on mrtopstep contact dannymrtopstepcom search for juno therapeutics juno q earnings surprise in store friday july   zacks equity research news stream juno therapeutics inc juno is expected to report secondquarter  results on aug  last quarter the company delivered a negative earnings surprise of  year to date juno’s shares have soared  while the industry recorded an increase of  the company’s poor track record so far shows negative surprises in three of the last four quarters the average negative earnings surprise for the last four quarters is  juno therapeutics inc price and eps surprise juno therapeutics inc price and eps surprise  juno therapeutics inc quote factors at play with no approved products in its portfolio juno does not generate any product revenue yet thus investors’ focus will primarily be on the company’s cash burn and pipeline updates juno is developing cellbased cancer immunotherapies based on car and highaffinity tcr technologies this is a hot therapeutic area with huge commercial potential presently the company’s most advanced pipeline candidates include jcar and jcar which use car tcell technology to target cd jcar is in a phase i study for nonhodgkin lymphoma nhl and in a phase iii study in pediatric and young adults with acute lymphoblastic leukemia rr all a pivotal trial for jcar in rr dlbcl diffuse large bcell lymphoma is expected to start in  the company plans to bring jcar to the market for nhl as early as  and for multiple indications by the end of  encouraging data from an earlystage study evalauting jcar in patients with chronic lymphocytic leukemia cll who failed treatment with ibrutinib was presented in dec  insights from studies of jcar are being applied to the development of jcar for the treatment of bcell malignancies however the company faced a major setback last year related to the development of its lead pipeline candidate jcar in nov  juno announced that it is discontinuing the development of jcar for rr all due to the toxicity witnessed in a phase ii rocket study we note that at the time of releasing the firstquarter results juno has maintained its expectations of cash burn of – million for  earnings whispers our proven model does not conclusively show that juno is likely to beat estimates this quarter this is because a stock needs to have both a positive earnings esp and a zacks rank  strong buy  buy or  hold for this to happen this is not the case here as you will see below zacks esp the earnings esp which represents the difference between the most accurate estimate and the zacks consensus estimate is  this is because both the most accurate estimate and the zacks consensus estimate are pegged at a loss of  centsyou can uncover the best stocks to buy or sell before they’re reported with our earnings esp filter zacks rank although juno’s zacks rank  buy increases the predictive power of esp its  earnings esp makes surprise prediction difficult we caution against all sellrated stocks  or  going into the earnings announcement especially when the company is seeing negative estimate revisions stocks that warrant a look here are some other worthconsidering health care stocks which have the right combination of elements per our model to post an earnings beat this quarter zoetis inc zts is scheduled to release results on aug  with an earnings esp of  and a zacks rank  you can see the complete list of today’s zacks  rank stocks here tesaro inc tsro is scheduled to release results on aug  the company has an earnings esp of  and a zacks rank  esperion therapeutics inc espr is expected to release results on aug  the company has an earnings esp of  and a zacks rank  more stock news tech opportunity worth  billion in                  from driverless cars to artificial intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the future zacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential see these stocks now want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report juno therapeutics inc juno free stock analysis report tesaro inc tsro free stock analysis report esperion therapeutics inc espr free stock analysis report zoetis inc zts free stock analysis report to read this article on zackscom click here zacks investment research original article link follow mrtopstep in our social space zacks equity research  posts delta print charts advertisement live squawk latest closing printsubscribe to the opening print mrtopstep tweets by mrtopstep follow mrtopstep juno therapeutics juno q earnings surprise in store  mrtopstepcom skip to content want to advertise on mrtopstep contact dannymrtopstepcom search for juno therapeutics juno q earnings surprise in store friday july   zacks equity research news stream juno therapeutics inc juno is expected to report secondquarter  results on aug  last quarter the company delivered a negative earnings surprise of  year to date juno’s shares have soared  while the industry recorded an increase of  the company’s poor track record so far shows negative surprises in three of the last four quarters the average negative earnings surprise for the last four quarters is  juno therapeutics inc price and eps surprise juno therapeutics inc price and eps surprise  juno therapeutics inc quote factors at play with no approved products in its portfolio juno does not generate any product revenue yet thus investors’ focus will primarily be on the company’s cash burn and pipeline updates juno is developing cellbased cancer immunotherapies based on car and highaffinity tcr technologies this is a hot therapeutic area with huge commercial potential presently the company’s most advanced pipeline candidates include jcar and jcar which use car tcell technology to target cd jcar is in a phase i study for nonhodgkin lymphoma nhl and in a phase iii study in pediatric and young adults with acute lymphoblastic leukemia rr all a pivotal trial for jcar in rr dlbcl diffuse large bcell lymphoma is expected to start in  the company plans to bring jcar to the market for nhl as early as  and for multiple indications by the end of  encouraging data from an earlystage study evalauting jcar in patients with chronic lymphocytic leukemia cll who failed treatment with ibrutinib was presented in dec  insights from studies of jcar are being applied to the development of jcar for the treatment of bcell malignancies however the company faced a major setback last year related to the development of its lead pipeline candidate jcar in nov  juno announced that it is discontinuing the development of jcar for rr all due to the toxicity witnessed in a phase ii rocket study we note that at the time of releasing the firstquarter results juno has maintained its expectations of cash burn of – million for  earnings whispers our proven model does not conclusively show that juno is likely to beat estimates this quarter this is because a stock needs to have both a positive earnings esp and a zacks rank  strong buy  buy or  hold for this to happen this is not the case here as you will see below zacks esp the earnings esp which represents the difference between the most accurate estimate and the zacks consensus estimate is  this is because both the most accurate estimate and the zacks consensus estimate are pegged at a loss of  centsyou can uncover the best stocks to buy or sell before they’re reported with our earnings esp filter zacks rank although juno’s zacks rank  buy increases the predictive power of esp its  earnings esp makes surprise prediction difficult we caution against all sellrated stocks  or  going into the earnings announcement especially when the company is seeing negative estimate revisions stocks that warrant a look here are some other worthconsidering health care stocks which have the right combination of elements per our model to post an earnings beat this quarter zoetis inc zts is scheduled to release results on aug  with an earnings esp of  and a zacks rank  you can see the complete list of today’s zacks  rank stocks here tesaro inc tsro is scheduled to release results on aug  the company has an earnings esp of  and a zacks rank  esperion therapeutics inc espr is expected to release results on aug  the company has an earnings esp of  and a zacks rank  more stock news tech opportunity worth  billion in                  from driverless cars to artificial intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the future zacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential see these stocks now want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report juno therapeutics inc juno free stock analysis report tesaro inc tsro free stock analysis report esperion therapeutics inc espr free stock analysis report zoetis inc zts free stock analysis report to read this article on zackscom click here zacks investment research original article link follow mrtopstep in our social space zacks equity research  posts delta print charts advertisement live squawk latest closing printsubscribe to the opening print mrtopstep tweets by mrtopstep follow mrtopstep juno therapeutics inc junoo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile juno therapeutics inc junoo related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse junoo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description juno therapeutics inc juno incorporated on august   is a biopharmaceutical company which is focused on developing cellular immunotherapies for the treatment of cancer the company is developing cellbased cancer immunotherapies based on its chimeric antigen receptor car and t cell receptor tcr technologies to genetically engineer t cells to recognize and kill cancer cells its product candidates jcar jcar and jcar as well as an additional early stage product candidate incorporating a fully human binding domain leverage car technology to target cd a protein expressed on the surface of almost all b cell leukemias and lymphomas its car product candidate jcar targets cd a different protein commonly expressed on the surface of b cell leukemias and lymphomasthe company has begun a phase i trial in relapsed or refractory rr multiple myeloma at memorial sloan kettering cancer center msk of a car product candidate that targets bcell maturation antigen bcma and incorporates a fully human binding domain and a bb costimulatory domain it is conducting phase i trials for four additional product candidates using its car technology directed against lcam lewis y muc and ror it is also conducting two phase iii clinical trials for a fifth product candidate using its tcr technology directed against wt lcam lewis y muc ror and wt are proteins that are overexpressed or aberrantly expressed on certain cancer cells its muc directed product candidate is an armored car that secretes the cytokine interleukin  il which may help to overcome the inhibitory effects that the tumor microenvironment can have on t cell activity muc is a protein overexpressed in the majority of ovarian cancersjcar is in development for adults with rr aggressive nonhodgkin lymphoma nhl and pediatric patients with relapsed or refractory acute lymphoblastic leukemia rr all jcar is being evaluated at fred hutchinson cancer research center fhcrc in a phase iii trial as a treatment for adults with any of several b cell malignancies including acute lymphoblastic leukemia all nhl and chronic lymphocyctic leukemia cll in patients relapsed or refractory to standard therapies jcar is a cddirected product candidate that uses a cd costimulatory domain and a cd and cd selection step to select out t cells from peripheral blood mononuclear cells jcar is designed for the treatment of b cell malignancies jcar is being tested in a phase i trial at the nci in pediatric and young adult patients that have cdpositive rr all or relapsed or refractory nonhodgkin lymphoma rr nhlthe company is exploring the potential of its car and tcr technologies against targets that have the potential to treat cancers beyond b cell malignancies and multiple myeloma in particular difficulttotreat solid organ tumors such as certain breast lung and pancreatic cancers cd is a cellsurface adhesion molecule that plays an important role in the development of a normal nervous system lewis y is expressed in multiple types of cancer such as lung leukemia breast and ovarian cancers ror is a protein expressed in the formation of embryos and jcar is its rordirected car t cell product candidate its tcr t cell product candidate jtcr targets wt an intracellular protein that is overexpressed in a number of cancers including adult myeloid leukemia aml and nonsmall cell lung breast pancreatic ovarian and colorectal cancers it is developing a car product candidate that targets a cytokine receptor ilra which is overexpressed on glioblastomathe company competes with novartis kite amgen national cancer institute cellectis servier johnson  johnson transposagen biopharmaceuticals bluebird bio bellicum celyad cell design labs nantkwest intrexon ziopharm md anderson cancer center unum therapeutics adaptimmune glaxosmithkline immunocellular therapeutics adicet bio autolus pfizer abbvie astrazeneca bristolmyers incyte merck roche regeneron corvus and macrogenics » full overview of junoo company address juno therapeutics inc  westlake ave n ste seattle   wa    p f  company web links home page officers  directors name compensation howard pien  hans bishop  sunil agarwal  steven harr  hyam levitsky  » more officers  directors juno therapeutics inc news update kite to launch midstage leukemia trial in fourth quarter  jun   kite cart gets fda priority review juno shares fall may   briefjuno therapeutics reports q loss per share  may   european ride service gett buys us rival juno for  million apr   european ride service gett buys us rival juno for  mln apr   » more junoo news related topics stocksstock screenerhealthcarebiotechnology  medical research juno therapeutics juno q earnings surprise in storehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballjuno therapeutics juno q earnings surprise in storezacks equity researchzacksjuly  reblogsharetweetsharejuno therapeutics inc juno is expected to report secondquarter  results on aug  last quarter the company delivered a negative earnings surprise of year to date juno’s shares have soared  while the industry recorded an increase of view photosthe company’s poor track record so far shows negative surprises in three of the last four quarters the average negative earnings surprise for the last four quarters is juno therapeutics inc price and eps surpriseview photosjuno therapeutics inc price and eps surprise  juno therapeutics inc quotefactors at playwith no approved products in its portfolio juno does not generate any product revenue yet thus investors’ focus will primarily be on the company’s cash burn and pipeline updatesjuno is developing cellbased cancer immunotherapies based on car and highaffinity tcr technologies this is a hot therapeutic area with huge commercial potential presently the company’s most advanced pipeline candidates include jcar and jcar which use car tcell technology to target cdjcar is in a phase i study for nonhodgkin lymphoma nhl and in a phase iii study in pediatric and young adults with acute lymphoblastic leukemia rr all a pivotal trial for jcar in rr dlbcl diffuse large bcell lymphoma is expected to start in  the company plans to bring jcar to the market for nhl as early as  and for multiple indications by the end of encouraging data from an earlystage study evalauting jcar in patients with chronic lymphocytic leukemia cll who failed treatment with ibrutinib was presented in dec  insights from studies of jcar are being applied to the development of jcar for the treatment of bcell malignancieshowever the company faced a major setback last year related to the development of its lead pipeline candidate jcar in nov  juno announced that it is discontinuing the development of jcar for rr all due to the toxicity witnessed in a phase ii rocket studywe note that at the time of releasing the firstquarter results juno has maintained its expectations of cash burn of – million for earnings whispersour proven model does not conclusively show that juno is likely to beat estimates this quarter this is because a stock needs to have both a positive earnings esp and a zacks rank  strong buy  buy or  hold for this to happen this is not the case here as you will see belowread morezacks esp the earnings esp which represents the difference between the most accurate estimate and the zacks consensus estimate is  this is because both the most accurate estimate and the zacks consensus estimate are pegged at a loss of  centsyou can uncover the best stocks to buy or sell before they’re reported with our earnings esp filterzacks rank although juno’s zacks rank  buy increases the predictive power of esp its  earnings esp makes surprise prediction difficultwe caution against all sellrated stocks  or  going into the earnings announcement especially when the company is seeing negative estimate revisionsstocks that warrant a lookhere are some other worthconsidering health care stocks which have the right combination of elements per our model to post an earnings beat this quarterzoetis inc zts is scheduled to release results on aug  with an earnings esp of  and a zacks rank  you can see the complete list of today’s zacks  rank stocks heretesaro inc tsro is scheduled to release results on aug  the company has an earnings esp of  and a zacks rank esperion therapeutics inc espr is expected to release results on aug  the company has an earnings esp of  and a zacks rank more stock news tech opportunity worth  billion in                  from driverless cars to artificial intelligence weve seen an unsurpassed growth of hightech products in recent months yesterdays sciencefiction is becoming todays reality despite all the innovation there is a single component no tech company can survive without demand for this critical device will reach  billion this year alone and its likely to grow even faster in the futurezacks has released a brandnew special report to help you take advantage of this exciting investment opportunity most importantly it reveals  stocks with massive profit potential see these stocks nowwant the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report juno therapeutics inc juno  free stock analysis report tesaro inc tsro  free stock analysis report esperion therapeutics inc espr  free stock analysis report zoetis inc zts  free stock analysis report to read this article on zackscom click here zacks investment researchreblogsharetweetsharerecently viewedyour list is emptywhat to read nextanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredmainstream model  holds promise  and peril  for teslaassociated pressthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderhow casino mogul steve wynn lost  million on baccaratbloombergdiscover it  out of  avg by k customersdiscover cardsponsoredchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekthe real reason overseas manufacturing is coming to americayahoo financethis will be in everyones household by banyan hillsponsoredhere are the us targets north korea most likely wants to nukebusiness insidertrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insideramazon has made half the profits of macy’s over the past  yearsquartzcardiologist  foods you should quit immediatelygundry mdsponsoredmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videoblue apron bullish calls not all theyre cooked up to bechrissy teigen is ‘so happy’ donald trump blocked her on twitterking kong this girl is an ugly mut  id block her if i was on twitter too join the conversation   news  events  juno therapeutics about usmanagement teamboard of directorsnewsour sciencescientific platformcar technologytcr technologypipelinetherapeutic areasinvestor relationsstock informationnews  eventssec filingsannual reportscorporate governanceinvestor faqworking at junocurrent job openingsnews  eventsupcoming eventsmore »datetitleaug   pm ptq  juno therapeutics earnings conference callpast eventsmore »there are no past events to display          datetitle jul  juno therapeutics to report second quarter  financial results on thursday august seattlebusiness wirejul   juno therapeutics inc nasdaq juno will announce financial results for the second quarter  on thursday august   after the close of usbased financial markets following the announcement juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at  pm pacific time pt   pm eastern time et anal jun  juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma–   overall response and   complete response at three months in core group moving to pivotal trial of those patients in response at three months   continue in response at six months –   of patients experienced no cytokine release syndrome or neurotoxicity in core group moving into pivotal trial –   of core group patients experienced severe neurotoxicity and   experienced severe cyt jun  court decides it lacks jurisdiction before fda approval occursseattlebusiness wirejun   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer announced today that the us district court for the district of delaware decided it lacked jurisdiction at this time over a lawsuit filed against kite pharma inc citing the absence of evidence that an fda approval decision of kite’s lead product candidate axicabtagene jun  juno therapeutics to present at the goldman sachs th annual global healthcare conferenceseattlebusiness wirejun   juno therapeutics inc nasdaq juno today announced that it will webcast its presentation at the goldman sachs th annual global healthcare conference at  am pt on tuesday june   the presentation will feature a business overview and update by hans bishop juno’s president and chief executive officer the webcast will be accessible on the investor relations page of juno’s website  jun  juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma– first multicenter car t trial to treat a wide range of patients with aggressive relapsed or refractory nhl excluded from other trials –   overall response rate and   complete response at three months in core analysis group moving into pivotal trial   of those patients with a response at three months continuing in response at six months –   of patients experienced severe neurotoxicity and   may  juno therapeutics appoints jay flatley to board of directorsseattlebusiness wiremay   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed jay flatley to its board of directors mr flatley is executive chairman of illumina inc a successful entrepreneur mr flatley brings to juno’s board his considerable experience building a highly successful and innovative  may  juno therapeutics to present key clinical data updates on jcar and jcar at the  american society of clinical oncology annual meetingseattlebusiness wiremay   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced that it will present key clinical updates in partnership with its collaborators on its investigational products jcar and jcar at the upcoming american society of clinical oncology asco annual meeting  in chicago illinois june   may  juno therapeutics to present at the bank of america merrill lynch  health care conferenceseattlebusiness wiremay   juno therapeutics inc nasdaq juno today announced that it will webcast its presentation at the bank of america merrill lynch  health care conference at  pm pt on tuesday may   the presentation will feature a business overview and update by steve harr juno’s chief financial officer and head of corporate development the webcast will be accessible on the investor relations page of jun may  juno therapeutics reports first quarter  financial results– initiated five trials with new binders technologies and targets – –  cash burn and operating burn guidance reaffirmed – – added key talent to leadership team – – eleven product candidates in clinical trials against eight different targets – – strong cash position of  million – – conference call today at  pm eastern time – seattlebusiness wiremay   juno therapeutic apr  juno therapeutics to report first quarter  financial results on thursday may seattlebusiness wireapr   juno therapeutics inc nasdaq juno will announce financial results for the first quarter  on thursday may   after the close of usbased financial markets following the announcement juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at  pm pacific time pt   pm eastern time et analysts apr  juno therapeutics appoints rupert vessey to board of directorsseattlebusiness wireapr   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed to its board of directors dr rupert vessey president of research and early development of celgene corporation dr vessey brings significant drug development capabilities to the juno board before joining celgene in januar apr  juno therapeutics appoints sunil agarwal as president of research and developmentexperienced executive addition with proven leadership and drug development expertise in emerging fields of medicine seattlebusiness wireapr   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed sunil agarwal md as president of research and development with dr agarwal’s appointment juno will bring r mar  juno therapeutics reports fourth quarter and  financial results– nine product candidates in clinical trials against eight different targets – – pivotal trial for jcar in rr dlbcl expected to start in  – – phase i jcar demonstrates  overall response and  complete response in rr dlbcl – – discontinuing development of jcar in rr adult all to focus on defined cell product in this setting – –  year end cash position of  million – –  feb  juno therapeutics to present at march  investor conferencesseattlebusiness wirefeb   juno therapeutics inc nasdaq juno today announced that it will webcast its presentations at two investor conferences in march the presentations will feature a business overview and update hans bishop juno’s president and chief executive officer will present at the cowen and company th annual health care conference at  am et on tuesday march    feb  juno therapeutics to report full year and fourth quarter  financial results on wednesday march seattlebusiness wirefeb   juno therapeutics inc nasdaqjuno will announce financial results for the fourth quarter and year ended december   on wednesday march   after the close of usbased financial markets following the announcement juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at  pm pacific time pt   pm eastern  jan  juno therapeutics appoints corsee d sanders as executive vice president and head of development operationsexperienced executive brings demonstrated operational excellence to juno will lead newly formed group focused on development operations seattlebusiness wirejan   juno therapeutics inc nasdaq juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced the appointment of corsee d sanders phd as executive vice president and head of development operations effect jan  juno therapeutics to present at the th annual jp morgan healthcare conferenceseattlebusiness wirejan   juno therapeutics inc nasdaq juno today announced that it will webcast its presentation at the th annual jp morgan healthcare conference at  pm pt on tuesday january   the presentation will feature a business overview and update by hans bishop juno’s president and chief executive officer the webcast will be accessible on the investor relations page of junos website at www  investor relations stock information news  events event calendar presentations sec filings annual reports  proxy statements corporate governance management team board of directors committee composition investor faq information request shareholder toolsprint pageemail pagerss feedsemail alertscontact  westlake avenue n suite  seattle wa   email inquiry juno is hiringbrowse our current job openings  juno therapeutics all rights reserved terms  conditions stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice